Call Us for Support
+91 9654860915
Finding access to medicine unapproved in your home country can feel overwhelming. We’re here to help you navigate the process, from your initial request to procurement coordination.
Submit your details and prescription to get started.Register today to get started on your medicine access journey.
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Order Ensartinib on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Betta Pharmaceuticals Co., Ltd.
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Ensartinib is a once-daily capsule for adults with non-small cell lung cancer (NSCLC) whose tumour tests positive for an ALK gene change. It was developed by Betta Pharmaceuticals Co., Ltd. in Hangzhou together with its US subsidiary Xcovery Holdings, and is sold in China as 贝美纳 (Beimena®). Its research code was X-396.
China's National Medical Products Administration (NMPA) first approved it in November 2020 and has since added two more uses. According to Betta's announcements, the Chinese approvals now cover:
An ALK-positive result has to come from a proper laboratory test on the tumour, so a lung cancer specialist will confirm this before suggesting it. Our lung cancer medicines page brings together other targeted options we help families import.
In some lung cancers, mostly adenocarcinomas, a piece of the ALK gene becomes fused to another gene. The fused protein stays switched on and keeps telling the cancer cells to divide. This medicine is a tyrosine kinase inhibitor that blocks that ALK signal. In laboratory work it also acted against several ALK mutations that make tumours stop responding to older ALK medicines, and it reaches the brain, where this cancer often spreads.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Who should not take it: anyone with a severe allergy to the active substance or any ingredient. The US capsules contain the yellow dye tartrazine, which can trigger allergic-type reactions, including asthma, in people sensitive to aspirin; check the ingredient list on the Chinese pack with your pharmacist. The figures below come from the US prescribing information, which pooled 458 patients.
Other points: serious side effects occurred in 23% of patients in eXalt3, most often pneumonia. It is broken down by the liver enzyme CYP3A and carried by P-glycoprotein, so moderate or strong blockers or boosters of CYP3A, and P-glycoprotein blockers, should be avoided; always tell the oncologist about every other medicine and herbal product. It can harm an unborn baby. Women who could become pregnant and men with such partners should use effective contraception during treatment and for 1 week after the last dose, and breastfeeding should stop for the same period. Its safety in children has not been established.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Each supply is brought in for a single named patient, requested either by the family or by the treating hospital, under India's rules for importing unapproved medicines. Please keep these ready:
Once we have checked a valid prescription and, where required, the import permit has been issued.
No. CDSCO has not approved it, so Indian pharmacies do not stock it. Outside China it is approved by the US FDA (as Ensacove®, December 2024), and Betta announced in November 2026 that the European Commission had also authorised it.
A patient can still receive it through the Named Patient Program (NPP), which lets a medicine without Indian registration be imported for one person on a doctor's prescription. We also help with other China-approved ALK inhibitors, for example iruplinalkib capsules.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. It is a capsule kept at room temperature, not in a fridge; the US label specifies 20°C to 25°C in the original bottle with its moisture-absorbing desiccant, and we follow the storage line printed on the Chinese pack. Boxes travel sealed under temperature-controlled shipping so they are not exposed to heat or damp on the way. Because the daily dose combines two strengths, each order includes both the 100 mg and 25 mg capsules in the right numbers. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
ALK-positive lung cancer is often treated for several years with a daily capsule, so a steady supply matters. When the prescription and permit are in place, we deliver to the cities listed here and to many other towns.
Thoracic oncology clinics in Delhi can send the ALK test report in the morning, and dispatch from New Delhi keeps the wait short.
For patients in Mumbai, we can deliver to the hospital where the brain and chest scans are reviewed, or to home.
Lung cancer patients in Bangalore get a clear count of 100 mg and 25 mg capsules for each month, so the two strengths never run short at different times.
In Chennai, we time each parcel around the liver and blood sugar checks the oncologist has planned.
Surgeons and oncologists in Hyderabad can request it for a patient starting treatment after a lung operation.
Families in Kolkata and the north-east get courier tracking details by message for every monthly box.
For Pune, we keep the next month's capsules moving before the current supply runs low, since doses should not be skipped.
Chest physicians in Ahmedabad can share the NGS or FISH report, and we tell them which papers are still pending.
Patients reviewed at hospitals in Vellore can collect the boxes at the hospital pharmacy during their visit.
Patients from Punjab, Haryana and Himachal treated in Chandigarh can have supplies sent ahead of each scan review.
In Lucknow, delivery can go to the patient's home or to the cancer institute handling follow-up.
Across Kerala, parcels are sent to Kochi or the town nearest the patient, packed to stay dry in the monsoon.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 20 November 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message